These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 18187210)

  • 1. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.
    Evans JF; Ferguson AD; Mosley RT; Hutchinson JH
    Trends Pharmacol Sci; 2008 Feb; 29(2):72-8. PubMed ID: 18187210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FLAP inhibitors for the treatment of inflammatory diseases.
    Sampson AP
    Curr Opin Investig Drugs; 2009 Nov; 10(11):1163-72. PubMed ID: 19876784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.
    Vickers PJ; Adam M; Charleson S; Abramovitz M; O'Neill G; Mancini JA
    J Lipid Mediat; 1993; 6(1-3):31-42. PubMed ID: 8357989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.
    Ferguson AD; McKeever BM; Xu S; Wisniewski D; Miller DK; Yamin TT; Spencer RH; Chu L; Ujjainwalla F; Cunningham BR; Evans JF; Becker JW
    Science; 2007 Jul; 317(5837):510-2. PubMed ID: 17600184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart disease. Gene suggests asthma drugs may ease cardiovascular inflammation.
    Wickelgren I
    Science; 2004 Feb; 303(5660):941. PubMed ID: 14963296
    [No Abstract]   [Full Text] [Related]  

  • 6. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.
    Dixon RA; Diehl RE; Opas E; Rands E; Vickers PJ; Evans JF; Gillard JW; Miller DK
    Nature; 1990 Jan; 343(6255):282-4. PubMed ID: 2300173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
    Gupta N; Nicholson DW; Ford-Hutchinson AW
    Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.
    Vickers PJ; Adam M; Charleson S; Coppolino MG; Evans JF; Mancini JA
    Mol Pharmacol; 1992 Jul; 42(1):94-102. PubMed ID: 1635556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of 5-lipoxygenase activating protein: WO 2008/030369.
    Tavridou A; Manolopoulos VG
    Expert Opin Ther Pat; 2009 Oct; 19(10):1473-6. PubMed ID: 19456278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein.
    Strid T; Svartz J; Franck N; Hallin E; Ingelsson B; Söderström M; Hammarström S
    Biochem Biophys Res Commun; 2009 Apr; 381(4):518-22. PubMed ID: 19233132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
    Charleson S; Prasit P; Léger S; Gillard JW; Vickers PJ; Mancini JA; Charleson P; Guay J; Ford-Hutchinson AW; Evans JF
    Mol Pharmacol; 1992 May; 41(5):873-9. PubMed ID: 1588922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.
    Evans JF; Lévillé C; Mancini JA; Prasit P; Thérien M; Zamboni R; Gauthier JY; Fortin R; Charleson P; MacIntyre DE
    Mol Pharmacol; 1991 Jul; 40(1):22-7. PubMed ID: 1857337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils.
    Cowburn AS; Holgate ST; Sampson AP
    J Immunol; 1999 Jul; 163(1):456-65. PubMed ID: 10384149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
    Gür ZT; Çalışkan B; Banoglu E
    Eur J Med Chem; 2018 Jun; 153():34-48. PubMed ID: 28784429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Lipoxygenase activating protein (ALOX5AP): association with cardiovascular infarction and stroke.
    Ben-Asher E; Lancet D
    Isr Med Assoc J; 2004 May; 6(5):318-9. PubMed ID: 15151378
    [No Abstract]   [Full Text] [Related]  

  • 17. Structure-based drug design on membrane protein targets: human integral membrane protein 5-lipoxygenase-activating protein.
    Ferguson AD
    Methods Mol Biol; 2012; 841():267-90. PubMed ID: 22222457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012).
    Hofmann B; Steinhilber D
    Expert Opin Ther Pat; 2013 Jul; 23(7):895-909. PubMed ID: 23600432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
    Bain G; King CD; Rewolinski M; Schaab K; Santini AM; Shapiro D; Moran M; van de Wetering de Rooij S; Roffel AF; Schuilenga-Hut P; Milne GL; Lorrain DS; Li Y; Arruda JM; Hutchinson JH; Prasit P; Evans JF
    Clin Pharmacol Ther; 2010 Apr; 87(4):437-44. PubMed ID: 20182424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
    Banoglu E; Çalişkan B; Luderer S; Eren G; Özkan Y; Altenhofen W; Weinigel C; Barz D; Gerstmeier J; Pergola C; Werz O
    Bioorg Med Chem; 2012 Jun; 20(12):3728-41. PubMed ID: 22607880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.